Log in

Biohaven Pharmaceutical News Headlines (NYSE:BHVN)

$43.01
+1.30 (+3.12 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
$41.02
Now: $43.01
$43.23
50-Day Range
$37.41
MA: $42.37
$48.84
52-Week Range
$29.17
Now: $43.01
$67.86
Volume610,462 shs
Average Volume755,348 shs
Market Capitalization$2.24 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.32

Headlines

Biohaven Pharmaceutical (NYSE BHVN) News Headlines

Source:
DateHeadline
Oppenheimer Analysts Give Biohaven Pharmaceutical (NYSE:BHVN) a $67.00 Price TargetOppenheimer Analysts Give Biohaven Pharmaceutical (NYSE:BHVN) a $67.00 Price Target
www.americanbankingnews.com - October 11 at 8:57 PM
Biohaven Pharmaceutical Holding Company Ltd.Biohaven Pharmaceutical Holding Company Ltd.
www.fool.com - October 10 at 7:41 PM
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Expected to Post Earnings of -$2.03 Per ShareBiohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Expected to Post Earnings of -$2.03 Per Share
www.americanbankingnews.com - October 2 at 9:37 PM
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Receives Average Rating of "Buy" from AnalystsBiohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 30 at 6:37 AM
Biohaven Pharmaceuticals (BHVN) "Buy" Rating Reaffirmed at William BlairBiohaven Pharmaceutical's (BHVN) "Buy" Rating Reaffirmed at William Blair
www.americanbankingnews.com - September 20 at 8:17 PM
Biohaven and Ra Pharma drugs selected for innovative ALS studyBiohaven and Ra Pharma drugs selected for innovative ALS study
seekingalpha.com - September 18 at 11:03 AM
Biohavens Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospitals Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)
finance.yahoo.com - September 18 at 11:03 AM
Biohaven completes enrollment in Phase 2/3 study of migraine med vazegepantBiohaven completes enrollment in Phase 2/3 study of migraine med vazegepant
seekingalpha.com - September 10 at 11:55 AM
Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference Late Breaking SessionBiohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference Late Breaking Session
finance.yahoo.com - September 10 at 11:55 AM
Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of MigraineBiohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
finance.yahoo.com - September 10 at 11:55 AM
Biohaven up 7% on accelerated rimegepant timelineBiohaven up 7% on accelerated rimegepant timeline
seekingalpha.com - September 4 at 11:16 AM
Biohaven Pharmaceuticals: An Intriguing CNS PlayBiohaven Pharmaceuticals: An Intriguing CNS Play
seekingalpha.com - August 23 at 6:44 PM
Biohaven Pharmaceutical: An Intriguing CNS PlayBiohaven Pharmaceutical: An Intriguing CNS Play
seekingalpha.com - August 23 at 6:44 PM
Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business DevelopmentsBiohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments
finance.yahoo.com - August 8 at 7:24 PM
Biohaven hits enrollment target in late-stage study of rimegepant for migraine preventionBiohaven hits enrollment target in late-stage study of rimegepant for migraine prevention
seekingalpha.com - August 7 at 7:19 PM
Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention TrialBiohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial
finance.yahoo.com - August 7 at 8:38 AM
Late-stage study underway for Biohavens verdiperstat in MSALate-stage study underway for Biohaven's verdiperstat in MSA
seekingalpha.com - July 31 at 7:08 PM
Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System AtrophyBiohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy
finance.yahoo.com - July 31 at 8:09 AM
Release Your 'Inner Spock' When Investing in Biotech StocksRelease Your 'Inner Spock' When Investing in Biotech Stocks
finance.yahoo.com - July 24 at 7:08 PM
FDA rejects Biohavens Nurtec application for ALSFDA rejects Biohaven's Nurtec application for ALS
seekingalpha.com - July 22 at 9:32 AM
Biohaven Provides Update On Phase 2/3 Alzheimers Disease Clinical Trial: Over 400 Patients EnrolledBiohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled
finance.yahoo.com - July 22 at 9:32 AM
Biohaven's treatment for Lou Gehrig's disease fails to win FDA nodBiohaven's treatment for Lou Gehrig's disease fails to win FDA nod
finance.yahoo.com - July 20 at 10:24 AM
The Week Ahead In Biotech: Pharma Earnings Pick Up PaceThe Week Ahead In Biotech: Pharma Earnings Pick Up Pace
feeds.benzinga.com - July 20 at 10:15 AM
Biohaven reveals positive results in migrane drug trialBiohaven reveals positive results in migrane drug trial
finance.yahoo.com - July 17 at 5:42 PM
Biohaven up 5% on publication of late-stage data on migraine med ZydisBiohaven up 5% on publication of late-stage data on migraine med Zydis
seekingalpha.com - July 15 at 5:56 PM
BHVN Crosses Above Key Moving Average LevelBHVN Crosses Above Key Moving Average Level
www.nasdaq.com - July 15 at 5:56 PM
Biohavens Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The LancetBiohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet
finance.yahoo.com - July 15 at 9:19 AM
Biohavens rimegepant successful in third late-stage migraine studyBiohaven's rimegepant successful in third late-stage migraine study
seekingalpha.com - July 11 at 9:08 AM
Biohaven Launches Demand More Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of MigraineBiohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine
finance.yahoo.com - July 11 at 9:08 AM
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term SafetyBiohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
finance.yahoo.com - July 11 at 9:08 AM
Biohavens Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of MedicineBiohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine
finance.yahoo.com - July 10 at 5:50 PM
2 Single Hitters That Could Score With the 'Write' Strategy2 Single Hitters That Could Score With the 'Write' Strategy
finance.yahoo.com - July 10 at 9:16 AM
Biohaven Offering Seems to Make Sale Less LikelyBiohaven Offering Seems to Make Sale Less Likely
finance.yahoo.com - July 5 at 5:32 PM
Enrollment underway in mid-stage study of Biohavens rimegepant in chronic pain conditionEnrollment underway in mid-stage study of Biohaven's rimegepant in chronic pain condition
seekingalpha.com - July 1 at 5:45 PM
Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal NeuralgiaBiohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia
finance.yahoo.com - July 1 at 9:16 AM
Biohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With Rimegepant, Oral CGRP Receptor AntagonistBiohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With Rimegepant, Oral CGRP Receptor Antagonist
finance.yahoo.com - June 24 at 5:05 PM
Biohaven prices stock offeringBiohaven prices stock offering
seekingalpha.com - June 19 at 7:41 AM
Biohaven Pharma -30% as public offering dampens takeover speculationBiohaven Pharma -30% as public offering dampens takeover speculation
seekingalpha.com - June 18 at 5:18 PM
BHVN Makes Notable Cross Below Critical Moving AverageBHVN Makes Notable Cross Below Critical Moving Average
www.nasdaq.com - June 18 at 5:18 PM
BHVN and DGLY among premarket losersBHVN and DGLY among premarket losers
seekingalpha.com - June 18 at 5:18 PM
Should Biohaven Pharmaceutical Holding (NYSE:BHVN) Be Disappointed With Their 36% Profit?Should Biohaven Pharmaceutical Holding (NYSE:BHVN) Be Disappointed With Their 36% Profit?
finance.yahoo.com - June 18 at 5:18 PM
Biohaven Pharma -13.4% after mixed shelf registrationBiohaven Pharma -13.4% after mixed shelf registration
seekingalpha.com - June 17 at 11:57 PM
Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) StockOptions Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock
www.nasdaq.com - June 11 at 6:14 PM
Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive CGRP-Targeting Monoclonal AntibodiesBiohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive CGRP-Targeting Monoclonal Antibodies
finance.yahoo.com - May 17 at 6:54 PM
Biohaven Pharmaceutical (BHVN) Presents At American Academy of Neurology Annual Meeting - SlideshowBiohaven Pharmaceutical (BHVN) Presents At American Academy of Neurology Annual Meeting - Slideshow
seekingalpha.com - May 10 at 6:07 PM
Biohavens migraine med rimegepant shows positive effect when dosed on scheduleBiohaven's migraine med rimegepant shows positive effect when dosed on schedule
seekingalpha.com - May 8 at 9:15 AM
Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation PlatformsBiohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms
finance.yahoo.com - May 7 at 9:13 AM
Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis® ODT Phase 3 Results At American Academy Of Neurology (AAN) 2019 Annual Meeting And New Data Release At Investor EventBiohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis® ODT Phase 3 Results At American Academy Of Neurology (AAN) 2019 Annual Meeting And New Data Release At Investor Event
finance.yahoo.com - May 3 at 9:22 AM
Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
finance.yahoo.com - May 2 at 7:05 PM
Interesting BHVN Put And Call Options For June 21stInteresting BHVN Put And Call Options For June 21st
www.nasdaq.com - April 30 at 6:11 PM
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel